Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685849 | 0.98 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL31474569 | 0.98 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL2298503 | 0.98 | KDM4E (0.67) | KDM4EALOX15TSHRACMSDTDP1 | |
| Hydrochloric Acid SCHEMBL17371709 | 0.96 | KDM4E (0.64) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2841904 | 0.88 | ECE1 (0.63) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL28041757 | 0.86 | KDM4E (0.52) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL6248220 | 0.84 | CYP1A2 (0.72) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL1958309 | 0.84 | P2RX7 (0.62) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL2237588 | 0.84 | P2RX7 (0.62) | KDM4EALOX15TSHRACMSDTDP1 | |
| Dipicolinic Acid SCHEMBL720696 | 0.83 | KDM4E (1.00) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105052-A1 | BIARYL ACID COMPOUNDS | PFIZER INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4646271-A1 | SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES | Mirati Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | claimed |
| CN-120023024-A | Combined collecting agent for lead-zinc sulfide ore flotation separation and application thereof | 昆明理工大学 | 2025-05-23 | — | — | CN | claimed |
| CN-118930969-B | Nucleating agent for improving wear resistance of PE material and preparation method and application thereof | 胡本巨 | 2025-04-18 | — | — | CN | claimed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| CN-118930969-A | Nucleating agent for improving wear resistance of PE material and preparation method and application thereof | 安徽元臻环保科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| CN-118491563-A | Preparation method of metal-organic framework supported iridium-based catalyst and photocatalytic CO2Reduction application | 大连理工大学 | 2024-08-16 | — | — | CN | claimed |
| WO-2024148150-A1 | SUBSTITUTED SPIROCYCLIC-PYRROLOQUINAZOLINONES AND SPIROCYCLIC-PIPERIDINOQUINAZOLINONES | Mirati Therapeutics, Inc. (US) | 2024-07-11 | — | — | WO | claimed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | claimed |
| EP-1313710-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Pfizer Products Inc. (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1305295-A1 | IMIDAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| US-20020119963-A1 | Imidazole derivatives | PFIZER PRODUCTS INC. | 2002-08-29 | — | — | US | claimed |
| US-20020103185-A1 | Pyrazole derivatives | PFIZER PRODUCTS INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002018346-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-03-07 | — | — | WO | claimed |
| WO-2002010141-A1 | IMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-02-07 | — | — | WO | claimed |
| EP-0159769-B1 | ELECTROCHEMICAL OXIDATION OF PYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1991-03-27 | — | — | EP | claimed |
| EP-0159769-A1 | Electrochemical oxidation of pyridine bases | REILLY INDUSTRIES, INC. (US) | 1985-10-30 | — | — | EP | claimed |
| US-4482439-A | Electrochemical oxidation of pyridine bases | REILLY TAR & CHEMICAL CORP. (US) | 1984-11-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103185-A1 | Pyrazole derivatives | CDK1, CDK5, CDK3 | KDM4E 1359/4885ALOX15 4454/4885TSHR 1218/4885 |
| US-20020119963-A1 | Imidazole derivatives | CDK1, CDK3, CDK2 | KDM4E 1120/4885ALOX15 4516/4885TSHR 1250/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | KDM4E 3348/4885ALOX15 743/4885TSHR 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.